Bilateral facial cutaneous angiomyolipomas: First case in the literature and a possible correlation with human immunodeficiency virus

Joshua Braganza, Ahmed Aljwaid, Mohammed Alazzawi, Abbas Alshami, Nitin S. Patel

A St. George’s University School of Medicine, Grenada
b Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, USA

ABSTRACT

Angiomyolipomas (AMLs) are benign tumors consisting of smooth muscle-like cells, adipocyte-like cells, and epithelioid cells. They are usually renal in origin, and extrarenal AMLs are rare. Cutaneous AMLs are even more rare. We present a case of 65 year old female, with no underlying genetic condition, who developed bilateral facial cutaneous AMLs. To the best of our knowledge, this is the first case in the literature. In addition, we investigate and suggest a correlation between human immunodeficiency virus and AMLs.

© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Angiomyolipomas (AMLs) are a subtype of tumor in a family of benign neoplasms that consist of smooth-muscle-like cells, adipocyte-like cells, and epithelioid cells [1]. Although they are typically renal in origin, extrarenal AMLs have rarely been reported, both sporadically and in association with rare genetic conditions [2,3]. The majority of reported extrarenal AMLs are hepatic and retroperitoneal, and cutaneous AMLs are even more uncommon [4,5]. We present a case of cutaneous AMLs manifesting as bilateral facial masses with no underlying genetic condition. To the best of our knowledge, this is the first case in the literature of its kind.

Case report

A 65-year-old woman with a medical history significant for rheumatoid arthritis, temporomandibular joint dysfunction, human immunodeficiency virus (HIV) for 20 years, asthma, and atrial fibrillation, presented with painless bilateral masses that she was feeling over her temples when yawning of one-month duration. The patient’s medications at the time were budesonide-formoterol fumarate 80–4.5 mcg 1 puff daily, hydroxychloroquine sulfate 200 mg BID, and prednisone 20 mg daily. For HIV, she was taking efavirenz-emtricitabine-tenofovir 600–200–300 mg daily for 6 years; however, she was switched to bictegravir-emtricitabine-tenofovir 50–200–25 mg daily 18 months ago. Physical examination revealed bilateral prominences over the temporal areas that were felt just superior to the temporomandibular joint. There was no clicking or dislocation, and the masses were minimally tender. There was no gingival swelling or swelling over the parotid areas. Ultrasonography revealed symmetric and heterogeneous focal masses, measuring 4.2 × 3.7 cm (left) and 4.4 × 4.5 cm (right), not typical for lipomas (see Figs. 1 and 2). Computed tomography (CT) scan of the head showed increased opacity in the temporal regions consistent with angiomylipoma’s hypertrophy of fat with the greatest thickness of 18 mm measured on the left side (see Fig. 3). Due to the benign nature of the masses, no biopsy was obtained.

Discussion

Imaging with CT scan is considered adequate to establish the diagnosis of AML [6,7]. The presence of regions of interest (ROI)-containing attenuations less than –10 HU can identify fat with high level of certainty [8]. Therefore, no biopsy was done in our patient, and the patient refused surgical removal for cosmetic reasons. Our extensive literature search identified no reported cases of bilateral facial cutaneous AMLs.
patients receiving highly active anti-retroviral therapy (HAART) that include protease inhibitors (PI) who later developed angiolipomas [10]. Lipodystrophy, in general, is a well-documented adverse effect in patients with HIV undergoing (HAART) with or without protease inhibitors (PI) [11,12]. Indeed, it has been reported in over 64 % of patients undergoing treatment with such therapy, but also was reported in HIV patients not yet on anti-retroviral treatment [13,14].

The pathogenesis of HIV-associated lipodystrophy is yet to be understood, but inhibition of mitochondrial enzymes, such as mitochondrial DNA polymerase-gamma enzyme, with resultant mitochondrial toxicity has been put forward as underlying mechanism, as biopsies from lipodystrophic tissues showed pronounced decrease in the number of mitochondria [15]. Other suggested mechanisms include disturbances in the function of the adipose tissue, elicited by alteration of the levels of adipocytokines (e.g. adiponectin) and pro-inflammatory markers (e.g. tumor necrosis factor-alpha) secreted by adipocytes in HIV patient on NRTIs and PIs [16,17].

Simultaneously, benign tumors of smooth muscle cells have also been reported in patients with HIV. [18] Kanitakis et al. reported that 8.3 % of patients with cutaneous leiomyoma in their practice had HIV, which was more prevalent than HIV in their population [19]. Knowing that HIV can predispose to angiolipomas and leiomyoma, we raise a concern that HIV can potentially predispose to AMLs as well, especially, if we know that adipose and muscle cells proliferation in AMLs, not with underlying genetic conditions, can originate from independent clonal origins [20]. If that holds to be true, this predisposition of AMLs by HIV can explain the increasing prevalence of AMLs noticed over the past five decades [21]. We believe that larger studies to investigate this presumed correlation are warranted.

Conclusion

Healthcare providers should be aware that angiomylipomas (AMLs) are benign and can be diagnosed by imaging to avoid unnecessary invasive workup. There might be a correlation between human immunodeficiency virus and AMLs, and larger studies are warranted to investigate such correlation.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Joshua Braganza: Writing - original draft, Visualization. Ahmed Aljwaid: Writing - original draft. Mohammed Alazzawi: Writing - review & editing. Abbas Alshami: Conceptualization, Investigation, Writing - review & editing, Project administration. Nitin S. Patel: Writing - review & editing, Supervision.

Declaration of Competing Interest

The authors declare no conflict of interest.
References

[1] Vos N, Oyen R. Renal angiomyolipoma: the good, the bad, and the ugly. J Belgian Soc Radiol 2018;102:41. doi:http://dx.doi.org/10.5334/jbsr.1536.

[2] Lin C, Jin L, Yang Y, et al. Tuberculous sclerosis-associated renal angiomyolipoma: a report of two cases and review of the literature. Mol Clin Oncol 2017;7:706–8. doi:http://dx.doi.org/10.3892/mco.2017.1377.

[3] Sun X, Feng R, Zhang Y, et al. Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma. BMC Pulm Med 2016;16:120. doi:http://dx.doi.org/10.1186/s12890-016-0286-1.

[4] Venyo ARG. A review of the literature on extrarenal retroperitoneal angiomyolipoma. Int J Surg Oncol 2016;2016:6347136. doi:http://dx.doi.org/10.1155/2016/6347136.

[5] Del Sordo R, Colella R, Leite S, et al. Cutaneous angiomyolipoma: a case report and literature review. Pathologica 2005;97:137–40.

[6] Park BK. Renal angiomyolipoma: radiologic classification and imaging features according to the amount of fat. Am J Roentgenol 2017;209:826–35. doi:http://dx.doi.org/10.2214/AJR.17.17973.

[7] Jinzaki M, Silverman SG, Akiha H, et al. Diagnosis of renal angiomyolipomas: classic, fat-poor, and epithelioid Types. Semin Ultrasound, CT MRI 2017;38:37–46. doi:http://dx.doi.org/10.1053/j.sult.2016.11.001.

[8] Simpson E, Patel U. Diagnosis of angiomyolipoma using computed tomography—region of interest ≤-10HU or 4 adjacent pixels ≤-10HU are recommended as the diagnostic thresholds. Clin Radiol 2006;61:410–6. doi:http://dx.doi.org/10.1016/j.crad.2005.12.013.

[9] Shetty K. Oral lipomatosis in antiretroviral therapy-associated lipodystrophy syndrome. J Oral Maxillofac Surg 2007;65:2095–9. doi:http://dx.doi.org/10.1016/j.joms.2006.05.046.

[10] Blanes M, Boix V, Belinchón I, et al. Angiolipomas, a rare manifestation of HIV-associated lipodystrophy. AIDS 2008;22:552–4. doi:http://dx.doi.org/10.1097/QAD.0b013e3282f56b7a.

[11] Baril J-G, Junod P, Leblanc R, et al. HIV-associated lipodystrophy syndrome: a review of clinical aspects. Can J Infect Dis Microbiol 2005;16:233–43. doi:http://dx.doi.org/10.1155/2005/303141.

[12] Ihezue K, Mason D. Biochemical manifestation of HIV lipodystrophy syndrome. Int J MCH AIDS 2012;1:92–101. doi:http://dx.doi.org/10.21106/ijma.6.

[13] Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30(Suppl 2):S125–42. doi:http://dx.doi.org/10.1086/313854.

[14] Motswaledi HM. Multiple nodules on the trunk and arms. Int J Dermatol 2010;49:1349–50. doi:http://dx.doi.org/10.1111/j.1365-4632.2010.04623.x.

[15] Walker LA. Update on mitochondrial toxicity: where are we now? J HIV Ther 2003;9:32–5.

[16] Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005;10:207–13.

[17] Janneh O, Hoggard PG, Tjoa JP, et al. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther 2003;8:417–26.

[18] Chadwick EG, Connor EJ, Hansen IC, et al. Tumors of smooth-muscle origin in HIV-infected children. JAMA 1990;263:3182–4.

[19] Kanatakis J, Carbonnel E, Chouvet B, et al. Cutaneous leiomyomas (piloleiomyomas) in adult patients with human immunodeficiency virus infection. Br J Dermatol 2000;143:1338–40. doi:http://dx.doi.org/10.1046/j.1365-2133.2000.03925.x.

[20] Cheng L, Gu J, Eble JN, Rostwick DG, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. Am J Surg Pathol 2001;25:1231–6. doi:http://dx.doi.org/10.1097/00000478-200110000-00002.

[21] Fittschen A, Wendlik I, Oeztuerk S, et al. Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients. Abdom Imaging 2014;39:1009–13. doi:http://dx.doi.org/10.1007/s00261-014-0129-6.